We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Beats on Earnings & Revenues in Q4
Read MoreHide Full Article
Cardinal Health Inc. (CAH - Free Report) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #3 (Hold) but that could change following its fourth-quarter fiscal 2017 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank(Strong Buy)stocks here. We have highlighted some of the key details from the just-released announcement below:
Earnings: Cardinal Health’s adjusted earnings rose 14.9% on a year-over-year basis to $1.31 per share. It also outpaced the Zacks Consensus Estimate of $1.24.
Revenues: Revenues increased 5% on a year-over-year basis to almost $33 billion, beating the Zacks Consensus Estimate of $32.8 billion.
Key Stats: Pharmaceutical revenues surged 5% to $29.6 billion while revenues from Medical segment increased 6% to $3.4 billion in the quarter.
Pharmaceutical segment revenues increased due to strong growth from the Specialty business and higher number of Pharmaceutical Distribution business customers. Higher contributions from net new and existing customers and solid performance in the post-acute segment were primarily responsible for the growth in Medical segment revenues.
The company expects adjusted earnings for fiscal 2018 in the range of $4.85 to $5.10 per share.
Check back later for our full write up on this Cardinal Health earnings report later!
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential.
Image: Bigstock
Cardinal Health (CAH) Beats on Earnings & Revenues in Q4
Cardinal Health Inc. (CAH - Free Report) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #3 (Hold) but that could change following its fourth-quarter fiscal 2017 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank(Strong Buy)stocks here. We have highlighted some of the key details from the just-released announcement below:
Earnings: Cardinal Health’s adjusted earnings rose 14.9% on a year-over-year basis to $1.31 per share. It also outpaced the Zacks Consensus Estimate of $1.24.
Revenues: Revenues increased 5% on a year-over-year basis to almost $33 billion, beating the Zacks Consensus Estimate of $32.8 billion.
Cardinal Health, Inc. Price and EPS Surprise
Cardinal Health, Inc. Price and EPS Surprise | Cardinal Health, Inc. Quote
Key Stats: Pharmaceutical revenues surged 5% to $29.6 billion while revenues from Medical segment increased 6% to $3.4 billion in the quarter.
Pharmaceutical segment revenues increased due to strong growth from the Specialty business and higher number of Pharmaceutical Distribution business customers. Higher contributions from net new and existing customers and solid performance in the post-acute segment were primarily responsible for the growth in Medical segment revenues.
The company expects adjusted earnings for fiscal 2018 in the range of $4.85 to $5.10 per share.
Check back later for our full write up on this Cardinal Health earnings report later!
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential.
See these stocks now>>